What’s happening to the GSK share price?

The GSK share price has been under pressure over the past 12 months. This Fool would avoid the company as it continues to struggle.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Syringe and vial on blue background

Image source: Getty Images

The GSK (LSE: GSK) share price has really struggled over the past year. Shares in the pharmaceutical company have fallen by 18%, excluding dividends.

Over the same time frame, the FTSE 100 has returned around 16%, excluding dividends.

Inflation Is Coming

Inflation is out of control, and people are running scared. But right now there’s one thing we believe Investors should avoid doing at all costs… and that’s doing nothing. That’s why we’ve put together a special report that uncovers 3 of our top UK and US share ideas to try and best hedge against inflation… and better still, we’re giving it away completely FREE today!

Click here to claim your copy now!

To put it another way, shares in GlaxoSmithKline have underperformed the market by 34%, excluding dividends over the past 12 months. 

Why has the stock performed so poorly, and should I take advantage of this underperformance and acquire some shares in the pharmaceutical giant for my portfolio? 

GSK share price doubts  

It would appear that the market has been giving Glaxo the cold shoulder because of doubts about the company’s growth potential.

While the business has a strong portfolio of treatments already on the market, analysts are expressing concern that the firm is not investing enough for the future. Its product pipeline, they argue, is thin compared to other companies such as AstraZeneca

I think this is a credible argument. If the company is not investing enough for the future, profits are unlikely to grow. That means the GSK share price could continue to tread water. 

Another headwind has been the coronavirus pandemic. During the first quarter, revenues fell 18% as patients delayed their shingles vaccinations (as well as other routine treatments).

This trend is likely to persist for the next few quarters. Unlike Astra, the company has struggled to develop its own coronavirus vaccine. This means it has to sit on the sidelines while its London-listed peer helps vaccinate the world. 

Growth initiatives 

The company is making progress in some areas. For example, it plans to launch a new HIV drug, a new long-acting treatment for severe asthma and there is the demerger of the £30bn Advil to Sensodyne consumer healthcare division. This is planned for the middle of 2022.

Analysts have long argued that Glaxo’s consumer healthcare business could be worth more as an independent operation. But unfortunately at this stage, it seems as if the market remains ambivalent about the potential demerger. 

Overall, I think the company’s outlook is uninspiring. However, I believe the involvement of US hedge fund Elliott Management, which recently acquired a significant stake in the business, could be a catalyst for change. 

Elliot has a reputation for being aggressive and forcing the companies in which it owns stakes to change. The hedge fund’s very involvement has already been a positive catalyst for the GSK share price. The stock has jumped around 5% since the position was revealed. 

The bottom line 

Considering all of the above, I think the outlook for the GSK share price remains mixed.

The way I see it, the stock’s most appealing quality today is its dividend yield. The shares offer a yield of 5.9%, but it is not guaranteed.

Management may have to cut the payout after the demerger or reduce shareholder distributions to free up more cash for research and development.

As such, I would not buy the stock today. I think the company’s dividend yield is on shaky ground, its growth outlook is uninspiring, and there’s no telling how the business will react to Elliott.

I’d rather buy other income stocks with better growth prospects for my portfolio. 

The Motley Fool UK's Top Income Stock...

We think that when a company’s CEO owns 12.1% of its stock, that’s usually a very good sign.

But with this opportunity it could get even better.

Still only 55 years old, he sees the chance for a new “Uber-style” technology.

And this is not a tiny tech startup full of empty promises.

This extraordinary company is already one of the largest in its industry.

Last year, revenues hit a whopping £1.132 billion.

The board recently announced a 10% dividend hike.

And it has been a superb Motley Fool income pick for 9 years running!

But even so, we believe there could still be huge upside ahead.

Clearly, this company’s founder and CEO agrees.

Learn how you can grab this ‘Top Income Stock’ Report now

Rupert Hargreaves owns no share mentioned. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Should you invest the value of your investment may rise or fall and your Capital is at Risk. Before investing your individual circumstances should be considered, so you should consider taking independent financial advice.

More on Investing Articles

Senior woman wearing glasses using laptop at home
Investing Articles

2 value stocks with high dividend yields to buy in July

Our writer examines two value stocks for his portfolio that marry low price-to-earnings ratios with high dividend yields.

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

Could I double my money buying at today’s Scottish Mortgage share price?

The Scottish Mortgage share price has crashed. Does that mean now could be a rewarding moment for our writer to…

Read more »

Hand holding pound notes
Investing Articles

Will the Lloyds dividend yield top 5%?

Our writer considers the outlook for the Lloyds dividend -- and what he should do about it.

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

3 ways I’m protecting my FTSE 100 stock portfolio right now

Jon Smith writes about several different ways he's trying to plan for the future to try to make his FTSE…

Read more »

Preparing a budget during a pandemic
Investing Articles

3 reasons I think the Aviva share price could double in 5 years

I'm not aiming to get rich quick, but today's Aviva share price makes me want to buy more and hold…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

The easyJet share price fell 10% last week. Here’s what I’m doing!

Last week saw the easyJet share price continue its poor performance. Here, this Fool weighs up if this is an…

Read more »

Lady wearing a head scarf looks over pages on company financials
Investing Articles

Are Royal Mail shares a buy today?

Royal Mail shares have experienced a drastic fall this year. In this article, Charlie Keough decides whether this is an…

Read more »

A bull outlined against a field
Investing Articles

2 FTSE 100 shares for the new bull market

I think the FTSE 100 is home to some promising companies such as these two I'd consider owning shares in…

Read more »